Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Quetiapine Monotherapy Shows Potential in Post-Traumatic Stress Disorder: Presented at WCBP By Jill Stein PARIS -- June 30, 2009 -- Quetiapine monotherapy appears to be an effective treatment for post-traumatic stress disorder (PTSD), according to data reported here at the 9th World Congress of Biological Psychiatry (WCBP) on June 29. Mark Hamner, MD, VA Medical Center, Charleston, South Carolina, and colleagues examined the efficacy of quetiapine monotherapy in patients with chronic PTSD. Dr. Hamner noted that the prevalence of PTSD may be as high as 30% in specific trauma populations such as combat veterans, adding that comorbidities are common among patients with PTSD. In fact, psychotic features may be present in up to 40% of combat veterans with chronic PTSD. The trial included patients aged 18 to 65 years who met DSM-IV criteria for chronic PTSD and had a baseline score at of at least 50 on the Clinician-Administered PTSD Scale (CAPS). Patients completed a 1-week placebo lead-in phase, after which placebo nonresponders were randomised to 12 weeks of double-blind treatment with either quetiapine or placebo. Eighty patients entered the study, and 77 had as least 1 efficacy assessment. The primary outcome measure was CAPS. Secondary rating instruments that were administered included the Positive and Negative Symptom Scale (PANSS), Clinical Global Impressions (CGI) Severity of Illness Scale (CGI-S), CGI Improvement Scale (CGI-I), Hamilton Rating Scale (HRS) for Depression (HRSD), HRS for Anxiety (HRSA), and other psychosocial and safety measures Patients treated with quetiapine showed a 3-fold greater improvement in CAPS global scores than placebo-treated patients (intent-to-treat analysis, last observation carried forward, P = .0070, 2-tailed). Quetiapine was also associated with significant improvements (versus placebo) for several secondary outcome measures: CAPS re-experiencing subscale, P = .0019; CAPS hyperarousal subscale, P = .030; CGI-S, P = .0030; CGI-I, P = .030; and PANSS composite scores, P = .0135. The HRSA (P = .020) and HRSD (P = .0093) also declined versus placebo. Adverse events were generally mild and consistent with the known safety profile of quetiapine. Dr. Hamner said that the data suggest that quetiapine is effective for treating PTSD. He also called for larger controlled trials to better delineate the role of quetiapine and other atypical antipsychotics in the management of patients with PTSD. Funding for this study was provided by AstraZeneca Pharmaceuticals LP. [Presentation Title: Quetiapine Monotherapy in the Treatment of Posttraumatic Stress Disorder: A Randomized, Controlled Trial. Abstract P-03-016] E-mail this page to a friend or colleague! To print, use this version